Developing a new treatment for metastatic melanoma using a specialized form of interleukin-2.
Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma
This study is testing a new treatment called CM-HZ01 that helps boost your immune system to fight metastatic melanoma by specifically activating certain immune cells, aiming to make the existing IL-2 therapy work better with fewer side effects for patients who don’t have many options left.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Celdara Medical, LLC NIH-funded |
| Lab location | 1 site (Lebanon, United States) |
| Project ID | NIH-11069291 on NIH RePORTER |
What this research studies
This research focuses on creating CM-HZ01, a novel therapeutic that enhances the immune response against metastatic melanoma by selectively activating CD8 T-cells. The approach aims to improve the effectiveness of interleukin-2 (IL-2) while minimizing side effects associated with traditional IL-2 therapies. By engineering a high avidity IL-2 super-agonist, the research seeks to provide a more targeted treatment option for patients who have limited effective therapies available. The goal is to advance this treatment to the investigational new drug (IND) stage, making it available for clinical use.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic melanoma who have not responded well to existing treatments.
Not a fit: Patients with early-stage melanoma or those who have not been diagnosed with melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with metastatic melanoma.
How similar studies have performed: Other research has shown promising results with similar immunotherapy approaches, indicating potential for success in this novel treatment.
Where this research is happening
Lebanon, United States
- Celdara Medical, LLC — Lebanon, United States (Active)
Researchers
- Principal investigator: Cooper, Colleen Doyle — Celdara Medical, LLC
- Study coordinator: Cooper, Colleen Doyle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.